Cargando…
Inflammation and immunity in ovarian cancer
The standard first-line therapy for ovarian cancer is a combination of surgery and carboplatin/paclitaxel-based chemotherapy. Patients with longer survival and improved response to chemotherapy usually present T-cell inflamed tumours. The presence of tumour-infiltrating T cells (TILs) notably varies...
Autores principales: | Salas-Benito, Diego, Vercher, Enric, Conde, Enrique, Glez-Vaz, Javier, Tamayo, Ibon, Hervas-Stubbs, Sandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569134/ https://www.ncbi.nlm.nih.gov/pubmed/33240443 http://dx.doi.org/10.1016/j.ejcsup.2019.12.002 |
Ejemplares similares
-
Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer
por: Aparicio, Belén, et al.
Publicado: (2022) -
Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants
por: Conde, Enrique, et al.
Publicado: (2021) -
The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1(+) tumour-infiltrating lymphocytes
por: Salas-Benito, Diego, et al.
Publicado: (2021) -
Neoantigens as potential vaccines in hepatocellular carcinoma
por: Repáraz, David, et al.
Publicado: (2022) -
New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis
por: Etxeberria, Iñaki, et al.
Publicado: (2020)